LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate. Read More

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

15th May 2014 13:31

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre Read More

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

1st May 2014 10:15

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i Read More

2 3 4 5 6 7 8 91011

FTSE 100 Latest

Value8,809.74

Change53.53